Inhibitors continued

Because of the continued need for better drugs to treat depression and the opportunities for new clinical indications, efforts to discover novel monoamine reuptake inhibitors continue unabated. This review will highlight developments in the discovery of novel agents that work via monoamine reuptake inhibition primarily based on publications that have appeared between 2005 and early 2007. New clinical indications for monoamine reuptake inhibitors will also be highlighted. A comprehensive review of publications on monoamine reuptake inhibitors between 2000 and July 2005 is available [3]. Approaches for the treatment of depression involving the augmentation of monoamine reuptake inhibitors with other CNS receptor modulators, and non-monoamine-based strategies have also been reviewed recently [6-8]. 

The central role that the PI3K/AKT pathway plays in cancer continues to fuel excitement in this arena as a potential target for cancer therapy. Progress with small molecule AKT inhibitors continues to be made, as judged by the compounds described in this review. However, the full scope of the clinical effectiveness of targeting this pathway has yet to be proven, as most of the reported small molecule AKT inhibitors are still in pre-clinical development, with only a few examples in early phase clinical trials. 

The search for additional new Abl inhibitors continued and at the 2004 meeting of the American Society of Hematology (ASH), Novartis disclosed an Abl kinase inhibitor with improved activity over imatinib [39]. The first literature report on AMN107 (3) appeared in early 2005 [40] (Scheme 2). The structure of AMN107 diverges from that of imatinib in two areas. First, the... 

TABLE 1-1. Partial list of clinically relevant cytochrome P450 substrates and inhibitors (continued)... 

Although many factors, such as film thickness and adsorption behaviour, have to be taken into account, the ability of a surfactant to reduce surface tension and contribute to surface elasticity are among the most important features of foam stabilization (see Section 5.4.2). The relation between Marangoni surface elasticity and foam stability [201,204,305,443] partially explains why some surfactants will act to promote foaming while others reduce foam stability (foam breakers or defoamers), and still others prevent foam formation in the first place (foam preventatives, foam inhibitors). Continued research into the dynamic physical properties of thin-liquid films and bubble surfaces is necessary to more fully understand foaming behaviour. Schramm et al. [306] discuss some of the factors that must be considered in the selection of practical foam-forming surfactants for industrial processes. 

Table 2 Current Clinical Trials of HDAC and DNMT Inhibitors (Continued)...

Fungicide research receives less attention by synthesis chemists in the United States than do the herbicide and insecticide disciplines. Overseas chemists find a much greater market for fungicides than do their American counterparts. One of the chapters indicates the interest of the Japanese in fungicides. Two chapters attest to England s contributions to fungicide chemistry. These ergosterol biosynthesis inhibitors continue to attract effort from around the world as evidenced by these workers and the reports from American authors. 

Proteinase Inhibitors (continued) PAI-2 PAI-3 (Protein C Inhibitor) Rises during pregnancy in 2nd trimester), decreased in pre-eclampsia Decreases during pregnancy <0.005 <4 X 10 Placenta 24 4 0.07 IPAI, 2PAI PAI2 HUMAN IPSP HUMAN... 

The influence of lipolysis inhibitors continues to be studied vigorously but their influence on the atherosclerotic process is uncertain. Nicotinic acid and various derivatives is the subject of many communications." It has been shown to prevent the FFA rise caused by... 

Another form of continuous application is by the nse of slightly soluble forms of solid inhibitors. The inhibitor (such as glassy phosphate or silicate in the form of a cartridge) is installed in a flow line where the inhibitor is continuously leached out by passage of fluid through the cartridge. Inhibitors in the form of sticks or pellets are used in oil and gas wells to supply inhibitor continuously by their natural slow dissolution (Fan et al. 2011). 

Gas wells corrode mostly in the reflux zone, which is an area of the well somewhere between the bottom and the wellhead, where condensation occurs. As the gas flows up the well, its temperature drops due to expansion, and this causes condensation when the temperature reaches the dew point of the gas. Volatile inhibitors such as formaldehyde and ammonia, injected into gas wells have been used successfully to inhibit corrosion. Many gas weUs today are protected by injecting amine inhibitors continuously, in batches, or by squeezing, which means they coat the well when injected and also enter the gas stream partially by vaporization and partially by entrainment. 

Because a dual-phase system may be treated with an inhibitor continuously or batchwise, the properties of the inhibitor should be selected to correspond with the treatment method. 

---